MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

38.52 -0.63 (-1.61%)
Official Closing Price Updated: 7:00 PM EDT, Apr 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,266,491
Open 39.13
Bid (Size) 38.61 (200)
Ask (Size) 38.80 (2,100)
Prev. Close 39.15
Today's Range 38.02 - 39.20
52wk Range 35.12 - 81.44
Shares Outstanding N/A
Dividend Yield 3.03%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap? ↗
Novo Nordisk stock has been stuck in a downward spiral for quite some time. 
Via The Motley Fool
News headline image
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met 
From Equity Insider
Via GlobeNewswire

Performance

YTD
-26.5%
-26.5%
1 Month
+4.4%
+4.4%
3 Month
-38.1%
-38.1%
6 Month
-27.6%
-27.6%
1 Year
-37.2%
-37.2%

More News

Read More
News headline image
Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins ↗
Via The Motley Fool
News headline image
Stock Market Today, April 21: Hims & Hers Health Drops as Amazon Unveils Competing Weight Loss Program ↗
Via The Motley Fool
Topics Stocks
News headline image
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly ↗
Via The Motley Fool
News headline image
Here's Why Agios Pharmaceuticals Crashed 23% Today ↗
Via The Motley Fool
News headline image
This Drug Stock Has Crushed the S&P 500 Over the Last Decade ↗
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
3 Ways to Invest in the Growing GLP-1 Weight Loss Market ↗
Via MarketBeat
News headline image
Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026? ↗
Via The Motley Fool
News headline image
Should You Forget CVS Health and Invest in a Purer Healthcare Play? ↗
Via The Motley Fool
News headline image
Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market ↗
Via The Motley Fool
News headline image
The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust ↗
Via The Motley Fool
News headline image
Could AbbVie Crash Lilly's Weight‑Loss Party? ↗
Via The Motley Fool
News headline image
The Global Pantry Reimagined: Unilever and McCormick Seal $65 Billion Merger Deal
Via MarketMinute
Topics Economy Supply Chain
News headline image
The "Daily Pill" Revolution: Eli Lilly’s Orforglipron Shatters Records with 25% Weight Loss
Via MarketMinute
News headline image
Which of These Healthcare Stocks Is More Likely to Be a Millionaire Maker? ↗
Via The Motley Fool
News headline image
3 Absurdly Cheap Dividend Stocks to Buy in April 2026 ↗
Via The Motley Fool
Topics Economy
News headline image
Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine
Via MarketMinute
Topics Artificial Intelligence
News headline image
Goldman Sachs Forecasts 12% S&P 500 Surge in 2026: The Five Pillars of a Maturing Bull Market
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
Via MarketMinute
Topics Economy World Trade
News headline image
Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals? ↗
Via MarketBeat
News headline image
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight ↗
Via The Motley Fool
News headline image
Earnings Revision Momentum: Why Analysts Upgraded S&P 500 Growth to 17%
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market ↗
Via The Motley Fool
News headline image
The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets
Via MarketMinute
Topics Intellectual Property

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 38.52
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 04/23/26 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story